Chardan Capital increased their price target on Krystal Biotech from $130.00 to $133.00 and gave the stock a “buy” rating in a research note on Monday, November 7th.

Source: https://www.etfdailynews.com/2023/02/18/krystal-biotech-inc-nasdaqkrys-shares-sold-by-allianz-asset-management-gmbh/

Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, February 10th.

Source: https://www.americanbankingnews.com/2023/02/28/arrowhead-pharmaceuticals-inc-nasdaqarwr-shares-acquired-by-point72-hong-kong-ltd.html

Finally, Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $111.00 to $107.00 in a research note on Tuesday, June 13th.

Source: https://www.etfdailynews.com/2023/08/10/canaccord-genuity-group-trims-intellia-therapeutics-nasdaqntla-target-price-to-65-00/

“Not wanting to leave Izzy’s two older brothers out, Danny and Charlie got a village named after them called Great Chardan.

Source: https://www.holdthefrontpage.co.uk/2023/news/former-sports-editor-wins-publishing-deal-for-books-inspired-by-daughter/